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ABSTRACT 
Background 
Invasive Candida infections (ICI) have emerged as an important cause of increased morbidity 
and mortality in specific patient populations in recent years. Multiple risk factors coupled 
with changes in epidemiology have made clinical management of these patients challenging. 
A laboratory-based surveillance project, Tracking Resistance to Antifungal drugs for Candida 
species in South Africa (TRAC-SA) was conducted at Chris Hani Baragwanath Hospital 
(CHBH) from 2009 to 2010 and allowed for collection of laboratory information related to 
episodes of candidaemia, delineation of the situation at the hospital and distribution of 
information to relevant stakeholders to help make informed clinical decisions.  
Objective 
Determine the clinical epidemiology and risk factors for bloodstream Candida infection at 
CHBH over an 18-month period  
Methods 
A retrospective, cross-sectional analysis was carried out on cases of blood culture-confirmed 
candidaemia from inpatients from 1 February 2009 until 31 August 2010.  These cases were 
identified from the TRAC-SA database, inpatient files were traced and clinical data recorded 
on a standard case report form. Additional laboratory data of selected tests done within 72 
hours of the initial blood culture were obtained from the National Laboratory Health Service 
Corporate Data Warehouse (CDW).   
Results 
A total of 167 episodes of candidaemia were identified during the study period with an 
incidence of 2.09 per 1000 admissions.  The distribution of episodes occurred among 55 
children (33%), 41 adults (25%) and 71 neonates (43%). The overall species distribution was 
Candida species other than C. albicans (98/167, 58.7%) and C. albicans (69/167, 41.3%).  
Candida species other than C. albicans comprised mainly of C. parapsilosis (73/167, 43.7%), 
C. glabrata (10.2 %, 17/167) and other species combined including C. tropicalis and C. 
krusei (8/167, 4.7%). Factors associated with C. albicans (versus Candida species other than 
C. albicans) infection included older age, use of 2 or more antibiotics, use of broad spectrum 
antibiotics specifically meropenem, aminoglycosides, vancomycin, co-trimoxazole and 
mechanical ventilation (p < 0.001). The overall case-fatality was 59/163 (35.3%). The highest 
case fatality was noted among adults with C. albicans infection, i.e. 15/22 (68.18%).  
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Significant risk factors associated with in-hospital mortality were use of central lines, urinary 
catheters, total parenteral nutrition, 2 or more antibiotics, beta lactam - beta lactamase 
inhibitors, proton pump inhibitors, aminoglycoside and abdominal surgery (p < 0.01). Of the 
C. parapsilosis isolates tested, 40 (57. 9%) tested non-susceptible to fluconazole.  Risk factors 
associated with fluconazole resistance included neonatal age, involvement of the respiratory 
system, mechanical ventilation, chemotherapy, use of a prior antifungal agent and use of 2 or 
broader spectrum antibiotics (p<0.01).  Of 71 neonates, 16 (22.5%) received empiric 
antifungals, in comparison to children (5/55, 9.0%) and adults (4/41, 9.7%) (p = 0.272).   
Conclusion 
CHBH had a high incidence of candidaemia with a predominance of Candida species other 
than C. albicans especially in the neonate age group. Risk stratification of in-patients is of 
paramount importance in choice of empiric antifungal drug due to the differing azole 
resistance patterns observed.  
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1 Chapter 1  
1.1 Introduction 
1.1.1 General  
Candida species are components of the commensal mucosal flora and skin among healthy 
human beings. They have the potential to cause infection of varying severity, ranging from 
localised to invasive Candida infections (ICI) with either secondary or multi-organ 
involvement. With advances in medical therapy, such as organ transplantation, life 
prolongation measures as well as an increase in immunocompromising diseases, the at-risk 
population and frequency of fungaemia has increased over the past decade (Shorr et al., 
2009).  In addition, individual risk factors such as extremes of age, low birth weight, use of 
invasive devices, broad spectrum antibiotics (Cotten et al., 2006), multiple site colonisation 
(Manzoni et al., 2006) and associated prolonged hospital stays (Blyth et al., 2009; Menzin et 
al., 2009; Zaoutis et al., 2005) have contributed to this increase. 
 
1.1.2 Morbidity and mortality due to candidaemia 
The mortality and morbidity associated with ICI is high. Crude and attributable mortality rates 
range from 11.9% (Blyth et al., 2009; Zaoutis et al., 2010; Gokcebay et al. 2016)) to 32.1% 
respectively among paediatric patients to 39%-71% and 49%-81% respectively among adults 
(Colombo et al., 2006; Eggimann et al., 2003; Gudlaugsson et al., 2003; Horn et al., 2009; 
Morgan et al., 2005; Pfaller and Diekema, 2007; Wey et al., 1988; Zaoutis et al., 2005). 
Attributable mortality in these studies was associated with nosocomial candidaemia, and 
subsequent increased length of stay, while higher mortality was noted in patients who had 
invasive devices like central catheters. Other contributory risk factors for both higher crude 
and attributable mortality rates in ICI include the species of Candida isolated (Hawkshead et 
al., 2016),  fluconazole resistance and virulence, (Abbas et al., 2000; Bliss et al., 2012; Viscoli 
et al., 1999), the underlying disease or intervention (Garnacho-Montero et al., 2010; 
Gokcebay et al. 2016) and the timing as well as choice of antifungal therapy (Savage et al, 
2015). In contrast,  fluconazole prophylaxis among high-risk infants has been shown to 
improve mortality rates and reduce ICI (Kaufman, 2003; Leibovitz, 2012; Manzoni et al., 
2007).  Morbidity is also considerable among infants, especially those with low birth weights 
and meningitis, with rates of up to 72% of neurodevelopmental disability post-ICI (Benjamin 
et al., 2010; Brian Smith et al., 2005, Barton et al.,2017). Associated hospital costs and 
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resource utilisation also escalates in relation to treatment of ICI.  (Arendrup, 2010; Craver et 
al., 2010; Hassan et al., 2009; Morgan et al., 2005; Smith et al., 2007; Zaoutis et al., 2010). 
Multiple risk factors  are shown to be associated with significant cost increases. These include 
initial treatment failure, length of stay prior to starting antifungals, fever and proven 
candidaemia (Armanganidis et al., 2017). Risk stratification of patients and early initiation of 
appropriate antifungal management has been shown to have a significant mortality benefit and 
cost reduction. (Eggimann and Ostrosky-Zeichner, 2010; Garey et al., 2006; Garnacho-
Montero et al., 2010; Morrell et al., 2005; Playford et al., 2010). An analysis  of the local 
epidemiology including resistance rates, antifungal use patterns and associated cost would 
allow for an appropriate containment strategy  to be implemented (Aysegul et al. 2016).  
 
1.1.3 Epidemiological shift in species distribution 
In the past decade, epidemiological shifts in species distribution have been noted in different 
parts of the world, with increasing proportions of Candida species other than C. albicans   
isolated from blood cultures (Falagas et al., 2010; Guinea et al., 2014; Goncalves et al., 2016). 
Multiple surveillance studies carried out in different parts of the world, showed temporal 
differences in species distribution and susceptibility depending on geographical area, hospital 
units and between adult, paediatric and neonatal patient populations.  
The Artemis DISK Global Antifungal Surveillance Study (1997 – 2003) was one of the 
biggest such programmes made up of 127 sites in 39 countries and included more than 
140000 isolates (Pfaller et al 2005, Guinea 2014).  Overall the frequency of C. albicans was 
shown to be decreasing in spite of it being the most common species isolated worldwide. 
Candida species other than C. albicans  such as C. glabrata were most often seen in the USA 
and Northern Europe rather than C. parapsilosis.  In contrast, the converse was more common 
in Brazil (Guinea 2014). This increase in C. glabrata has been observed in patients of 
increasing age prompting questions regarding mucosal immunity and colonisation in the 
aging population (Pfaller et al. 2002). Local hospital factors e.g. azole use and infection 
control protocols were postulated as significant variables which could impact on species 
distribution (Guinea et al., 2014; Goncalves et al., 2016). Nosocomial spread of infection 
could also account for the larger proportions of C. albicans and C. parapsilosis isolated in 
certain populations like neonates or patients in oncology. (Escribano et al. 2013; 
Asmundsdottir et al. 2008). Possible reasons for this include the increased use of interventions 
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like central venous catheters and long term indwelling ports in these patients and poor 
infection control.   
The Artemis and Sentry Antimicrobial Surveillance programme (1997- 2002) also examined 
susceptibility patterns amongst isolates (Pfaller et al 2002). With changes in species 
distribution, azole non-susceptibility associated with species such as C. parapsilosis and C. 
kefyr was shown to be increasing.  C. albicans demonstrated no consistent changes to 
fluconazole with overall C. glabrata demonstrated variable susceptibility patterns based on 
geographic region with rates of 10.6% in Asia-Pacific, 13.0% in Latin America and 16.5% in 
Europe.  Differences between sources of ICI, as well as the emergence of less common 
species like C. krusei  which exhibit fluconazole resistance, have had implications for 
prophylaxis and  empiric therapy (Pfaller et al., 2011b) especially in high-risk groups (Pfaller 
et al., 2010). Increased azole use has been implicated in changes in species distribution. 
Variable fluconazole susceptibility in species like C. parapsilosis have been noted in 
countries like Brazil and South Africa where more resistant organisms have been associated 
with outbreaks (Goncalves et al. 2016). Resistant organisms also place limitations in the 
usage of available antifungals (Govender et al., 2016).  With increasing use of echinocandins, 
baseline susceptibility profiles are important in determining trends in resistance. Low levels of 
resistance to all available echinocandins was noted except for C. glabrata isolates from North 
American isolates (Pfaller et al. 2010).  
Emergence of new resistance mechanisms and multidrug resistant fungi leading to 
breakthrough infections highlighted the need for long term monitoring of susceptibility 
profiles as well as emphasising the need for newer, molecular methods to determine 
mechanisms of resistance. An example of one such fungal pathogen is C. auris, first described 
in Japan in 2009. It has now emerged globally as a healthcare-associated  pathogen which has 
demonstrated resistance to multiple antifungal drug classes, difficult to identify in the 
laboratory and has the potential for nosocomial transmission. Patient populations involved are 
not limited to  critically ill , but also those with haematological conditions ( Vallabhaneni et al 
2016) In light of this, identification of variables potentially associated with fluconazole non 
susceptibility  (Garnacho-Montero et al., 2010)  or multi antifungal drug resistance are of 
paramount importance for initiating appropriate timeous management of patients.   
Different therapeutic strategies utilised for ICI has also had variable impact on species 
distribution and resistance patterns especially in ICUs. As Candida colonisation and ICI 
occurs along a continuum, choice of initial antifungal has been based on factors like number 
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of body sites colonised, co morbid conditions, biomarkers and previous drug exposure. The 
China -SCAN (China Survey of candidiasis in the ICU) and Amarcand2 study demonstrated  
a decrease in early hospital mortality in patients empirically commenced on an antifungal (Na 
Cui et al. 2017, Montravers et al. 2017). The majority of these participants were critically ill 
patients who cultured azole susceptible Candida isolates from sterile cultures. In contrast, the 
EMPIRICUS (Empirical Antifungal Treatment in ICUs) (Timsit et al., 2017) and MSG-01 
trial (Ostrosky-Zeichner et al. 2017), both used echinocandins empirically in critically ill 
patients with no significant change in mortality at 28 days. Candida colonisation indices and 
1, 3 beta-D (B-D) glucan assay, among other criteria, were used to try and risk stratify 
patients, in EMPIRICUS. Although these have been  have been previously shown to be useful 
in initiating therapy as well as lowering rates of ICI without affecting species distribution, the 
lack of impact on mortality implies that the either the clinical risk factors play a more 
significant part in choice of empiric antifungal or that the biomarkers used were insufficient.   
Pre-exposure to azoles and echinocandins has also been shown to decrease the prevalence of 
C. albicans in favour of less antifungal susceptible species like C. glabrata (Lotholary et al. 
2011). Consistent use of blind empiric therapy without documented cultures, would have not 
just selective pressure but also cost implications and affect species distribution.    
 
1.1.4 Laboratory-based diagnosis of candidaemia 
Timeous diagnosis of candidaemia is critical in optimising therapy and improving the 
outcome.  Additionally, isolation of yeasts from sterile specimens such as tissue and blood 
cultures has been relied upon for the diagnosis of fungaemia.  However, numerous problems 
associated with blood culture-taking practices contribute to yields as low as 6% (Kosmin and 
Fekete, 2008), as well as the possibility of negative yields even in the presence of 
disseminated fungaemia of up to 50% (Berenguer et al., 1993).  Histological demonstration of 
tissue invasion can provide a diagnosis. However, the risk associated with obtaining a 
representative specimen must be taken into account, especially in paediatrics.  
Current microbiology-based diagnostics still consist of conventional microscopy and culture-
based methods. Blood cultures taken for invasive candidaemia are limited by the delay due to 
incubation and slow turnaround time. When positive, microscopy usually consisting of a 
Gram stain of a yeast, can provide a rapid diagnosis  identification and aid in initiation of 
empiric therapy and search for complicated infection. Histological or microscopy techniques 
can be used to rapidly identify fungal elements for a provisional diagnosis. However, 
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definitive diagnosis relies on identification on either phenotypic or biochemical characteristics 
or both. Since this can take from 24 to 72 hours depending on the method (manual or 
automated) used, it leads to delays in commencing antifungal therapy. Development of 
chromogenic culture media and newer technology like the matrix-assisted laser desorption 
ionization time of flight (MALDI-TOF) have enabled faster identification of organisms. The 
MALDI-TOF is based on analysis of protein patterns that are compared to a database for 
species level identification.  It has been used to rapidly identify isolates both from culture as 
well as directly from blood cultures (Pulcrano et al. 2013; Rizzato et al.  2015). However, cost 
of the equipment at the outset is currently prohibitive for the public sector in South Africa.    
 Non-culture based methods utilising cell wall components, fungal DNA, fungal protein or 
surrogate markers of infection, are also applicable in patient management to provide 
prognostic information and/or permit therapeutic monitoring. Of these technologies, the 1, 3 
beta-D (B-D) glucan assay is available for routine use currently in South Africa in the public 
and private sector. Application of the 1, 3 beta-D (B-D) glucan assay has been mostly in 
certain at-risk groups such as haematology or oncology patients (Odabasi et al., 2004). 
However, there are still uncertainties with regards to use in paediatrics, as well as variability 
in performance depending on technical and host factors (Budhavari, 2009; Alexander and 
Pfaller, 2006). Recent studies have looked at the sensitivity of the assay in relation to the 
species implicated. This was found to be most sensitive with C. albicans and the lowest levels 
are seen in C. parapsilosis (Mikulska et al. 2016). Ideally, the 1, 3 beta-D (B-D) glucan assay 
can be used in patients at risk for candidaemia with follow up culture or non-culture based 
methods used for definitive identification of isolates for those with positive tests.  
Other biomarkers like procalcitonin (PCT), which is produced in response to infection, has 
been evaluated for the diagnosis of ICI. A large case control study by Peiralli et al (2017) 
examined cases of ICI in critically ill patients admitted to internal medical units and the 
associated PCT values. The conclusion was that PCT values greater than 2.5ng/ml had high 
negative predictive values for ICI when compared to bacterial infections. 
Various molecular techniques are available, mostly in the research or reference laboratory 
setting. The use of DNA sequencing has helped not only in species identification but also in 
detection of resistance mechanisms (Goncalves et al. 2016; Sidiq et al.  2016).  
1.1.5   Role of surveillance programmes 
Ideally surveillance programmes should be able to not only provide information regarding 
temporal and geographic trends in species distribution, but also demonstrate and help predict 
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trends in antifungal susceptibility and identify risk factors for invasive candidaemia. Design 
of the ideal surveillance programme should incorporate the following characteristics: long 
term study design on a global or national scale; standardised methodology for participating 
laboratories; provide confirmatory reference testing at central laboratories; use a central 
database; and have procedures in place to validate the data sent in by participating site.  
Programmes, such as the international Sentry Antimicrobial Program, have played a vital role 
in defining epidemiology, species distribution  and changing trends in antifungal 
susceptibility patterns  (Arendrup et al., 2011; Colombo et al., 2006; Pfaller and Diekema, 
2002).  Previously undefined risk factors have emerged as important entities. These include 
associations between the species isolated, and community-onset candidaemia  (Pfaller et al., 
2011c), age-related species distribution (Pfaller et al., 2010; Wisplinghoff et al. 2013; 
Hawkshead III et al., 2016), fluconazole resistance (Pfaller et al., 2011a) and geographic 
variation (Pfaller et al., 2011b).  
Studies encompassing the above traits are necessary to establish prevalence of both common 
and rare species and resistance phenotypes. These could then be tracked to determine trends, 
pre-empt and guide selection of antifungals.  However, most of these studies are laboratory-
based with limited clinical data which would help in defining management of ICI in the local 
setting.  
1.1.6   The South African perspective 
Considering the globally changing geographic trends in species distribution and antifungal 
resistance, local national surveillance studies are needed to delineate and compare trends 
between provinces and the different health provision sectors i.e. private and public.  These 
would also provide information regarding antifungal susceptibility and thus contribute to 
establishing specific treatment and preventative strategies including infection control.  
Local literature to date looks at both single and multi- centre studies  detailing Candida 
epidemiology (Arendse and Orth, 2008; Badenhorst et al., 1991). Although the Kreusch study 
was based at CHBH over a 13 year period and was the first to delineate Candida 
epidemiology in the hospital, it was limited by the inclusion of only adult patients (Kreusch et 
al, 2013).  The distribution of isolates was different between the above-mentioned studies: 
Candida species other than C. albicans dominated in paediatrics while C. albicans was 
prominent in adults. The surgical ICU and the general wards were the commonest settings for 
infections. Risk factors for candidaemia included abdominal surgery, HIV infection, diabetes 
mellitus, use of foreign devices and exposure to broad spectrum antibiotics (Kreusch et al, 
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2013).  The only study describing resistance patterns was by Govender et al where a worrying 
trend of azole non-susceptible C. parapsilosis isolates from both private and public sector 
hospitals limited choice of antifungal therapy in this resource limited setting (Govender et al, 
2016).  
From 1 February 2009 until 31 August 2010, Phase 1 of a laboratory-based sentinel 
surveillance project, TRAC, (Tracking Resistance to Antifungal drugs for Candida species in 
South Africa) was carried out in collaboration with 11 university affiliated or regional public-
sector hospitals and ≥85 private sector hospitals served by the 5 largest amalgamated private 
pathology practices across South Africa. The major objectives of this project were to: describe 
the species distribution of Candida spp. causing bloodstream infection at sentinel sites in 
South Africa, compare the species distribution and describe the prevalence of resistance to 
nine antifungal drugs (including fluconazole, voriconazole, amphotericin B, caspofungin). 
During that period, 407 cases of ICI were recorded from CHBH, the largest number of cases 
from any participating public-sector hospital in South Africa.   
This is the first study, nested within TRAC-SA surveillance, to characterise the clinical 
epidemiology of invasive candidaemia at CHBH in both adult and paediatric patients and to 
evaluate the risk factors and features associated with azole resistance.    
 
1.2 Specific aim 
To describe the clinical epidemiology and risk factors for candidaemia at CHBH from 
February 2009 through August 2010 
 
1.3 Objectives 
1.3.1 Primary objective 
To describe the epidemiology of laboratory-confirmed invasive candidaemia at CHBH 
from 1 February 2009 until 31 August 2010. 
1. To describe the demographics of hospitalised patients with laboratory-confirmed 
invasive candidaemia 
2. To describe the clinical management of patients with laboratory-confirmed invasive 
candidaemia with regard to antifungal therapy 
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3. To describe the species distribution and antifungal drug resistance  
 
1.3.2 Secondary objectives 
1. To describe clinical risk factors for patients with lab-confirmed invasive candidaemia 
2. To describe the clinical risk factors for fluconazole-resistant Candida infection  
3. To compare the epidemiology of patients with fluconazole-susceptible and 
fluconazole-resistant invasive Candida infection 
 
1.4 Methods 
This cross sectional retrospective study aimed to describe the clinical epidemiology and risk 
factors for candidaemia from inpatients between 1 February 2009 until 31 August 2010 
admitted to Chris Hani Baragwanath Hospital (CHBH) in Soweto, Gauteng, South Africa. 
This is an academic hospital with a bed capacity of approximately 3200. It offers a number of 
specialist services including oncology, infectious diseases, neurosurgery, intensive care 
(neonatal, paediatric, surgical), trauma and general medicine facilities.   
The hospital was a participant of the Tracking Resistance to Antifungal drugs for Candida 
species in South Africa (TRAC – SA) surveillance system. This was national laboratory based 
surveillance intended to describe characteristics of episodes of candidaemia amongst patients 
at sentinel sites in the private and public health sectors in South Africa from 1 February 2009 
to 31 August 2010. It included all incident episodes of blood culture confirmed candidaemia 
from any patient during the specified time period.  
 Basic laboratory information regarding species identification and limited antifungal 
susceptibility on isolates obtained at the CHBH laboratory was submitted with the isolate to 
the Centre for Opportunistic, Tropical and Hospital Infections (COTHI) at the National 
Institute for Communicable Diseases (NICD) in South Africa for microbiological 
confirmation, antifungal susceptibility testing and further characterisation if necessary. The 
episode was logged on the TRAC SA database as an episode.   Of the episodes with mixed 
cultures i.e. more than 1 species isolated, the most resistant isolate was included in the 
analysis. The mixed cultures identified from the blood culture bottle at the reference 
laboratory were numbered e.g. 123A, 123B and matched a single CHBH laboratory number. 
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1.4.1 Definitions 
An incident episode was defined as the first isolation of a Candida species from a patient’s 
blood culture.  Any episode occurring more than 30 days (definition based on previously 
published studies) thereafter was classified as a new episode. If subsequent positive blood 
cultures for Candida species were drawn from the same person >30 days after the first 
isolation, the first of these cultures defined a recurrent episode of candidaemia for that 
individual.  For this study, patients were classified according to their admitting sections i.e. 
neonates either born at CHBH or transferred from other hospitals are admitted to the Neonatal 
unit, paediatrics (<18 years) and adults (≥ 18 years).  The neonatal unit is comprised of 3 units 
– Intensive Care Unit which admits patients requiring ventilation, high care or transitional 
care unit (babies not requiring ventilation but still having central lines, receiving TPN, etc.) 
and neonatal ward (babies without any central lines admitted for weight gain).  These 
definitions were used as patients were not moved from their admitting sections if they 
changed age categories during their hospital stay.  
For this retrospective file review patients with blood culture-confirmed candidaemia at CHBH 
were identified from the surveillance database and files were retrieved from medical records. 
Data was collected on a case report form (Appendix 5.3). This included demographic 
information, risk factors for candidaemia, concomitant conditions, complications, antifungal 
therapy, and clinical outcome. Additional laboratory data of selected tests done within 72 
hours of the initial blood culture was obtained from the National Laboratory Health Service 
Corporate Data Warehouse (CDW).  
1.4.2 Microbiologic methods 
1.4.2.1   CHBH 
Standard operating protocols were followed for phenotypic identification and susceptibility 
testing of Candida species at the CHBH laboratory. This consisted of subculture from the 
blood culture broth onto Sabouraud Dextrose agar (Diagnostic Media Products, National 
Health Laboratory Service, Johannesburg, South Africa). Species identification was based on 
germ tube production and the Auxacolor Yeast Identification system (Biorad, France). 
Antifungal susceptibility testing was done with E tests (bioMerieux, France) for fluconazole 
and voriconazole on RPMI media (bioMerieux and Diagnostic Media Products). The isolate 
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was sub cultured onto Dorset transport medium (Diagnostic Media Products) for submission 
to COTHI. 
1.4.2.2 COTHI 
Species identification was confirmed using morphologic and biochemical criteria. Isolates 
were initially inoculated onto chromogenic agar (MAST ID CHROMagar Candida, Mast 
Diagnostic, Amiens, France) to determine whether more than one species was present. 
Subsequent identification to species level was by one or more of the following biochemical 
kits or instruments: Vitek 2 YST, API 20C AUX and API ID 32C (bioMerieux, Marcy 
l’Etoile, France).  
Antifungal susceptibility testing for fluconazole, voriconazole, posaconazole, itraconazole, 
flucytosine, micafungin and anidulafungin was performed using pre-prepared dried 
microbroth dilution panels containing Alamar blue (Thermo Fisher Scientific, Cleveland, OH, 
USA). MIC values were determined visually following 24 h of incubation. MICs of 
amphotericin B were determined by Etest (bioMerieux) on RPMI 1640 plates containing 2% 
glucose (Diagnostic Media Products).  Any isolate with an initial resistant MIC was retested 
with Etest (bioMerieux).  
1.4.3 Statistical analysis 
This was performed with STATA version 11(StataCorp LP, USA) and a p value of <0.05 was 
considered significant. Continuous variables were compared with Student’s T test and 
categorical variables compared with Fisher’s exact test.  
1.4.4 Ethics 
Approval for the TRAC-SA surveillance study as well as the retrospective review were 
obtained from the Human Ethics review committee (Medical), University of the 
Witwatersrand, Johannesburg (Approval number M120613) and the CHBH hospital 
management.  
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2 Chapter 2 
2.1 Results 
 
 
Figure 1. Flowchart of all episodes logged on the database 
1 
                                                 
1  
Episode – Incident/first culture of Candida species from blood culture within a 30 day period.   
Mixed – more than 1 species isolated from the same blood culture bottle as per the reference lab  
Recurrent – Any episode occurring after the incident culture in a 30 day period  
 
403 episodes
302 episodes (75%)
135 episodes and patients excluded 
(patient records not found)
167 episodes (55%) included
166 patients
(patient records located)
67 mixed episodes (25 patients) 1
34 recurrent episodes (14 patients) 1
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A total of 403 episodes of candidaemia were documented from February 2009 until August 
2010.  Of these, 166 patients (167 episodes) with completed case report forms were included 
for analysis (Figure 1). Some blood cultures were obtained at different times, sometimes in 
multiple sets, and the site was not often stated e.g. peripheral or central line.   
Overall, 135 patients were excluded from the study as the records could not be located in the 
archives and 167 episodes (166 patients) were included. Some patients had both mixed and 
multiple cultures. Basic demographics obtained from the laboratory of both included and 
excluded groups are shown below. The age and prior antifungal category showed significant 
differences between both groups (age, p <0.001; prior antifungal given, p <0.001). For 
neonates, a significantly higher percentage (>50%) of records could not be located compared 
to other age groups  
Table 1. Demographic characteristics of included (167 files found and included in study) and 
excluded (135 files not found and excluded from study) patient (302) groups 
Characteristic Totals 
Files found 
n =167 
Number (%) 
Files not found 
n=135 
Number (%) 
p value 
Age    <0.001 
Neonates 168 71 (42.3) 97 (57.7)  
Paediatrics 70 55 (78.6) 15 (21.4)  
Adults 64 41 (64.1) 23 (35.9)  
Gender    0.513 
Male 141 75 (53.2) 66 (46.8)  
Female 161 92 (57.1) 69 (42.9)  
Species    0.642 
C. albicans 124 69 (55.6) 55 (44.4)  
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Characteristic Totals 
Files found 
n =167 
Number (%) 
Files not found 
n=135 
Number (%) 
p value 
Non C. albicans 178 98 (55.1) 80 (44.9)  
Fluconazole resistance       
Total 55 41 (74.5) 14 (25.5) 0.853 
C. parapsilosis 52 40 (76.9) 12 (23.1) 0.577 
Antifungal prior to BC    <0.001 
Fluconazole 33 27 (81.8) 6 (18.2)  
Amphotericin B 20 15 (75.0) 5 (25.0)  
 
2.1.1 General patient demographics 
Of 167 episodes, 55 occurred in children (33%), 41 in adults (25%) and 71 in neonates (43%). 
The overall age range for patients was birth to 90 years (median 6 months, interquartile range 
(IQR) 14.6 days – 12 years). The median age and IQR for each group was: neonates, 15 days 
(IQR 6-24 days); children, 2 months (IQR 11 months – 10 years) and adults, 44 years (IQR 
30-57 years).    
Combined, the age group from birth to 4 years of age made up 113 (67.6%) of episodes. 
Within the neonate group, 62/71 (87.3%) of babies were low birth weight (LBW), i.e. < 2500 
g and 68/71 (95.8%) were premature < 37 weeks gestation (median 30 weeks; IQR 27-32 
weeks). Of these, 13 (21.1 %) were extremely low birth weight (ELBW) at <1000 g (median 
890 g (IQR 785-935g). There was no significant difference in gender distribution of 
candidaemia (females, 92/167 (55.0%) compared to males, 75/167 (44.9%); p = 0.115)).   The 
proportion of new-born baby boys was 52% (39/75) compared to male children (21/75; 
28.0%) and adult males (15/75; 20%) (p=0.051).    
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Figure 2. Gender distribution by age category 
 
2.1.2 Distribution of candidaemia within the hospital 
The majority of episodes 71/167 (42.5%) occurred in neonates compared to the adult group 
(41/167; 24.5%) and the paediatric group 55/167(32.9%). A significantly higher number of 
patients 15/41 (36.5 %) of cases from adult general medicine (Figures 2 and 3) compared to 
adult ICU (10/41; 24.4%) (p= 0.031).   There were significant differences in species 
distribution within the age groups. Within the adult group, species distribution varied with C. 
albicans predominant (11/15; 73.3%) in general medicine, C. parapsilosis (5/9; 55.6%) in 
general surgery and C. glabrata (5/10; 50.0%) in ICU (p= 0.002).  The neonatal unit had a 
different distribution with C. parapsilosis being the commonest in the unit (42/71, 59.1%), 
while C. albicans was predominant in the paediatric general medical units (13/29; 44.8%) (p= 
0.002).  
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Figure 3. Species distribution in adult wards 
 
 
 
Figure 4. Species distribution in paediatric and neonatal wards 
 
 
2.1.3 Incidence and in-hospital parameters 
Incidence of candidaemia was highest in the paediatric ICU (3.13/100) admissions followed 
by neonates (2.90/100 admissions). The median length of stay of any inpatient was 31 days 
(IQR 12-48 days) while the median time spent in hospital prior to the first positive blood 
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culture was 13 days (IQR 4-22 days). The median length of stay for patients with non C. 
albicans infections was 44 days compared to 34.4 days for C. albicans infections (p=0.318). 
Comparisons between neonates and paediatrics, and neonates and adults of overall length of 
stay and length of stay prior to the first positive blood culture are shown in Table 2. 
 
Table 2. Total length of stay in hospital and length of stay prior to positive blood culture per 
age category 
 
Neonates 
Total 71 
Paediatrics 
Total 55 
Adults 
Total 41 
p value 
Overall length of stay 
(Median, IQR) 
37 days, 
20-62 days 
26 days, 
10-43 
days 
19 days, 
10-36 
days 
*N vs. P p= 0.009 
P vs. A p= 0.375 
N vs. A p= 0.002 
Length of stay prior to 
positive blood culture 
(Median, IQR) 
15 days,  
7-23 days 
9 days,  
1-16 days 
13 days, 
1-22 days 
N vs. P p= 0.02 
P vs. A p= 0.573 
N vs. A p= 0.211 
*N – neonates; P- paediatrics; A-adults 
 
2.1.4 Mortality 
Outcome was known for 163 patients. Of these, 59 (35.3%) patients died with 28/59 (47.4%) 
being adults.  The species isolated in this age group was significant: C. albicans was cultured 
from 15/28 (53.57%) adults and 7/13 (53.84%)   paediatric patients who died while in 
neonates 11/18 (61.1%) C. parapsilosis was isolated (P = 0.006). Case fatality ratios were not 
significantly different in adults admitted to the general medical wards [(12/28, 42.8 %) 
compared to those admitted in ICU (10/28; 35.7%) (P = 0.123). Of 59 patients who died, 35 
(59.3%) died within 7 days of admission. Of 37/166 patients with either confirmed HIV or 
HIV exposure, 13/37 (35.1%) died compared to 129/166 (77.7%) of HIV negative patients. 
(p=0.532) The CD4 count was available for 14 HIV-seropositive patients, 7 of whom had 
advanced immunosuppression with CD4 < 200 (median CD4 count 198; IQR 33-975). 
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Table 3. Case fatality ratios based on species and age category 
Species Neonates Paediatrics Adults 
Number demised/total isolates (%) 
C. albicans 6/18 (33.33) 7/29 (24.14) 15/22 (68.18) 
C. parapsilosis 11/42 (26.19) 4/22 (18.18) 3/9 (33.33) 
C. glabrata 1/7 (14.29) 1/1 (100.0) 9/9 (100.0) 
C. krusei 0/2 (0) 0/1 (0) 0/0 (0) 
Other* 0/2 (0) 1/2 (50.0) 1/1 (100.0) 
*Includes C. krusei, C. tropicalis, C. lusitaniae 
Table 4. Univariate analysis of risk factors for mortality 
Risk factors  
Total with 
intervention 
Number 
demised 
Number 
survived 
p value 95% CI OR 
Mechanical ventilation 80 34 46 0.101 0.93 - 1.00 0.97 
Central lines 119 53 66 0.001 0.85 - 0 .95 0.90 
Urinary catheter 40 24 16 <0.001 0.88 - 0.96 0.92  
Total parenteral nutrition  9 7  2 0.019  0.83 - 0.98 0.90 
Abdominal  surgery 34 18 16 0.025  0.92  - 0.99 0.95 
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Risk factors  
Total with 
intervention 
Number 
demised 
Number 
survived 
p value 95% CI OR 
2 or more antibiotics 109 33 76 0.027 1.09 - 4.1 2.13 
Beta lactam- beta lactamase inhibitor 36 22 14 0.001 0.91 - 0.97 0.94  
Proton pump inhibitor 7 6 1 0.025  0.85 - 0.98 0.91 
Aminoglycoside 83 23 60 0.023 1.00 - 1.03 1.01 
Chemotherapy 15 3 12 0.182 0.98 - 1.06 1.02 
Steroids 44 19 25 0.261  0.95 - 1.01 0.98 
 
The significant risk factors on univariate analysis noted for mortality included use of central lines, urinary catheters, total parenteral nutrition, 2 or 
more antibiotics, beta lactam - beta lactamase inhibitor, proton pump inhibitor, aminoglycoside and abdominal surgery (Figure 3). 
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2.1.5 Laboratory results 
2.1.5.1   Microbiology 
2.1.5.1.1 Isolates 
Of 167 episodes analysed, Candida species other than C. albicans (98/167; 58.68%) were 
more frequently isolated than C. albicans (69/167; 41.31%). Within the Candida species other 
than C. albicans group. C. parapsilosis was the commonest species isolated (73/167; 3.7%) 
followed by C. glabrata at 10.2 % (17/167).   
 
 
Figure 5. Distribution of species isolated 
 
C. parapsilosis n=73
C. albicans n=69
C. glabrata n=17
C. krusei n=3
Other (C.tropicalis,
C.lusitaniae) n=5
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Figure 6. Species distribution per age category 
 
C. parapsilosis isolation was significantly higher in neonates (42/73; 57.5 %) compared to 
children (22/73; 30.1%) and adults (9/73; 12.3%) (p = 0.002). Adult patients also had the 
highest number of C glabrata at 52.9% (9/17) compared to neonates at 41.1% (7/17) 
(p=0.003) (Figure 6).  
Within the low birthweight groups, 39/62 (48. 39%) of isolates were Candida species other 
than C. albicans species specifically C. parapsilosis. Of this group, 23/39 (58.9%) were in the 
VLBW category (< 1500 g).  Of the 4 babies who cultured C. glabrata, 3 were diagnosed 
with necrotising enterocolitis during their hospital stay not requiring surgery. Their initial 
admission was for respiratory distress and all were premature.  
At NICD, 13 patients were diagnosed with mixed infections. Of all these episodes, 9 had 3 
species identified while the rest had dual species candidaemia. The commonest combinations 
of organisms were C. albicans and C. parapsilosis. Of these mixed cultures, the fluconazole 
MIC reflected that of the most resistant isolate present. This was mainly C. parapsilosis with 
high fluconazole MICs. 
2.1.5.1.2 In vitro susceptibility  
Antifungal susceptibility results for fluconazole and voriconazole were available for 161 and 
143 episodes respectively. All C. albicans isolates were uniformly susceptible to both drugs. 
Of the C. parapsilosis isolates tested, 40 (57.9%) were non-susceptible to fluconazole with 30 
isolates having MICs >256 (high level resistance).  Discordant fluconazole susceptibilities 
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which showed very major errors (category change e.g. susceptible to resistant) was observed 
for 18 C. parapsilosis and 15 C glabrata isolates between the reference and originating 
laboratory. All 40 C. parapsilosis isolated tested susceptible to caspofungin, though this is not 
the recommended agent for in vitro susceptibility testing.  
Overall 24/167 (14.3%, p=0.009) of patients received an antifungal either empirically or 
prophylactically. Neonates 16/71 (22. 5%) received a similar proportion of antifungals in 
comparison to paediatrics (5/55, 9.0%) and adults (4/41, 9.7%) (p = 0.272). Of the 24 
episodes, 21 patients (81. 2%) received fluconazole and 18.7% received amphotericin B. 
Azole resistant C. parapsilosis was isolated in 38 patients.  Of these, 10/38 (26.3%) received 
fluconazole prophylactically/empirically compared to 5/31 (16.1%) fluconazole susceptible C. 
parapsilosis which was not significant (p= 0.06). Overall 141/167 (84.43%) of episodes were 
treated with an antifungal drug.  Amphotericin B was used in 30/44 (68.2%) episodes treated 
in neonates while fluconazole was used for 32/71 (45.0%), 26/55(47.2%) and 27/41(65.8%)   
episodes in neonates, children and adults respectively.  
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Significant risk factors on univariate analysis for fluconazole resistance included falling in the neonate category, involvement of the respiratory system, 
mechanical ventilation, use of a prior antifungal and use of 2 or broader spectrum antibiotics including beta lactams, cotrimoxazole and 
aminoglycosides. (Table 5) 
Table 5. Risk factors for fluconazole resistance 
 Fluconazole    
 Total tested (n) 
Susceptible 
n (%) 
Resistant  
n (%)* p value 95% CI OR 
Age     <0.001 1.65-5.03 2.89 
Neonates  69 40 (57,97) 29 (42,03)    
Adults 40 36 (90,00) 4 (10,00)    
Ward    <0.001 1.69 5.17 2.96 
Neonates 68 39 (57,35) 29(42,65)    
Paediatrics 53 45(84,91) 8(15,09)    
Adults 40 36 (90,00) 4(10,00)    
Systems    0.919  0.92-1.07 0.99 
Respiratory 74 48(64,86) 26(35,14)    
Cardiac 5 3(60,00) 2(40,00)    
GIT 31 25(80,65) 6(19,35)    
CNS 8 7(87,50) 1(12,50)    
Skeletal 1 1(100,00) 0(0,00)    
Malignancy Haem 10 10(100,00) 0(0,00)    
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 Fluconazole    
 Total tested (n) 
Susceptible 
n (%) 
Resistant  
n (%)* p value 95% CI OR 
Malignancy Solid 13 12(92,31) 1(7,69)    
Burns 4 3(75,00) 1(25,00)    
NEC 5 2(40,00) 3(60,00)    
Renal 1 0(0,00) 1(100,00)    
Metabolic 9 9(100,00) 0(0,00)    
Lines 99 83(83,840 16(16,16) 0.625 0.93-1.03 0.98  
Urinary catheter 41 32(78,05) 9(21,95) 0.550 0.96-1.06 1.01  
Mechanical ventilation 78 51(65,38) 27(34,62) 0.011 0.90-0.98 0.94 
Total parenteral nutrition 9 7(77,78) 2(22,220 0.818  0.93-1.09 1.00  
Abdominal surgery 35 23(65,710 12(34,29) 0.179   0.93-1.01 0.97 
Nosocomial sepsis 32 21(65,630 11(34,38) 0.815  0.97-1.01 0.99 
More than 2 antibiotics 107 74(69,160 33(30,840 0.031 0.16-0.91 0.38 
3rd generation 
cephalosporin 52 44(84,62) 8(15,380 0.046 1.00-1.07 1.03 
Beta lactam-Beta 
Lactamase Inhibitor 37 33(89,190 4(10,810 0.026 1.00-1.09 1.05 
Fluconazole 25 17(68,000 8(32,00) 0.416  0.95-1.02 0.98 
Amphotericin B 14 7(50,000 7(50,00) 0.035 0.92-0.99 0.95 
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 Fluconazole    
 Total tested (n) 
Susceptible 
n (%) 
Resistant  
n (%)* p value 95% CI OR 
Proton pump inhibitor 7 5(71,430 2(28,57) 0.847 0.93-1.05 0.99 
Meropenem 52 33(63,460 19(36,54) 0.028  0.94-0.99 0.97 
Vancomycin 43 29(67,44) 14(32,56) 0.215  0.96-1.00 0.98 
Aminoglycoside 81 54(66,67) 27(33,33) 0.023 0.96-0.99 0.98 
*Resistant includes susceptible-dose dependent isolates 
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2.1.5.2 Blood results 
Blood tests either done on admission or for a septic workup were C reactive protein (normal value <10 mg/ml), white cell count (WCC) (Range 3.90-
12.60 x 109/L) and platelet counts (range 186-454 x109/L) taken within 72 hours of the incident blood culture (Table 6).  The highest CRP and white 
cell counts were seen in adults (median 166.65, IQR 79.78-213.46 and median 9.75, IQR 7.14-16.95 respectively). The lowest platelet counts were 
observed in neonates (median 102, IQR 41-249).  
1. 3 β- D glucan assays were done for 16 patients within a 72-hour window either prior or subsequent to the blood culture draw. Of these 11/16 
(68.7%) were positive.  Of the 4/16 (25.0%) were negative and 1/16 (6.2%) was equivocal. Of the positive results, 72.7% (8/11) were neonates who 
had cultured C. albicans and 2/11 (18.18%) cultured C. parapsilosis. Negative results (75%, 3/4) occurred in paediatric oncology patients from whom 
blood had been drawn from the ports and whose blood cultures were positive for C. albicans.   
Table 6. Laboratory parameters 
Laboratory parameters Total 
Neonates 
N=71 
Total 
Paediatrics 
N=55 
Total 
Adults 
N = 41 
p value 
CRP (mg/ml) 55 
Median 19.44 
(IQR 2.23-16.27) 
42 
Median 41.28 
(IQR 14.74- 79.48) 
25 
Median 166.65  
(IQR 79.78-213.46) 
N vs P p=0.006 
P vs A p=0.00 
N vs A p=0.00 
White cell count x (109/L) 60 
Median 10.61  
(IQR 6.34-16.27) 
47 
Median 6.78  
(IQR 1.51-15.43) 
34 
Median 9.75 
(IQR 7.14-16.95) 
N vs P p=0.072 
P vs A p=0.026 
N vs A p=0.884 
Platelets 
(x109/L) 
60 
Median 102  
(IQR 41-249) 
34 
Median 163  
(IQR 27-398) 
47 
Median 186 
(IQR 79-417) 
N vs P p=0.088 
P vs A p=0.348 
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Laboratory parameters Total 
Neonates 
N=71 
Total 
Paediatrics 
N=55 
Total 
Adults 
N = 41 
p value 
N vs A p=0.007 
1.3 β -D glucan 
(ug/ml) 
5 
Median 523 (IQR 
500 -523) 
7 
Median 35.5 (IQR 8-
240) 
1 
Median 523 
(IQR 523-523) 
N vs P p= 0.008 
P vs A p=0.130 
N vs A p=0.694 
*N – neonates; P- paediatrics; A-adults 
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2.1.6 Clinical conditions and risk factors 
Within neonates and children, the commonest clinical diagnosis or reason for admission 
involved the respiratory system e.g. pneumonia, with 55/71 (77.4 %) and 17/55 (30.9%) 
respectively. GIT conditions included trauma and NEC and comprised of 15/41 (36.5%), 9/55 
(16.3%) and 12/71 (16. 9%) in the adult, children and neonate groups respectively. There 
were 24 oncology patients comprising 18/24 (75%) paediatric and 6/24 (25%) adults. This 
included those with either solid organ involvement or haematological malignancies. Of the 
paediatric oncology patients, 17/18 (94.4%) were receiving chemotherapy compared to adult 
oncology patients (2/6; 33.3%) (p <0.001, 95% CI 1.06 - 1.16; OR 1.11) 
HIV exposure was noted in 24/71 (33.8%) neonates and diagnosed in 9/55 (16.3%) and 4/41 
(9.75%) paediatric and adult patients respectively.  The HIV-exposed neonates received 
antiretroviral drugs as part of the prevention of mother- to-child (PMTCT) HIV transmission 
programme. Of the 23/24 (95.81%) babies for whom information regarding the mode of 
delivery was known, there was no significant association between babies delivered by 
Caesarean section 12/23 (52.1%)   and those delivered by normal vaginal delivery 11/23 
(47.8%) (p = 0.160).   In this HIV exposed group, the species distribution was not significant 
14/24 (58.3%) C. parapsilosis. 8/24(33.3%), C. albicans and 2/24 (8.3%) and C. glabrata 
(p=0.460).  At the time of the positive blood culture 29/73 (39.7%) of infections in neonates 
were classified as nosocomial sepsis i.e. onset of sepsis more than 72 hours after admission. 
 
Figure 7. System involved as per clinical diagnosis per age category 
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Risk factors associated with C. albicans versus Candida species other than C. albicans 
include the age - neonates, children under 1 year and adults older than 65 years -  ward, use of 
2 or more antibiotics, use of broad spectrum antibiotics specifically meropenem, 
aminoglycosides, vancomycin, co-trimoxazole and mechanical ventilation (Table 4).  Overall 
C. albicans was the commonest species isolated in HIV exposed or positive patients (18/37, 
48.6%)   compared to HIV negative patients (51/130, 39.2%) (p = 0.650)  
Of the 18 adults with non C. albicans candidaemia, 12/18 (66.6%) had GIT involvement and 
subsequent surgery compared to 6/18 (33.3%) who had involvement of other systems 
(p=0.155) Significant risk factors in oncology patients included use of central lines or ports. 
surgical intervention (either insertion or removal of a port) and use of steroids (p < 0.005).  
 
Table 7. Species associated risk factors 
 Total  
C. albicans 
Number (%) 
*Candida 
species other 
than C. 
albicans   
Number (%) p value 
Age group     
Neonates 71 18 (25,4) 53 (74,6) <0.001 
<1 year 93 28 (30,1) 65 (69,9)  
>65 yrs. 
 
4 0 (0) 
3 (100,0)  
Ward          
Neonates 71 18 (25,4) 53 (74,6) 0.001 
Paediatric 56 30 (53,6) 26 (46,4)  
Adults 41 22 (53,7) 19 (46,3)  
          
Gender 167 69 (41,3) 98(58,7) 0.115 
Male 75 26 (34,7) 49(65,3)   
Female 92 43 46,7) 49(53,3)   
          
Mortality     
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 Total  
C. albicans 
Number (%) 
*Candida 
species other 
than C. 
albicans   
Number (%) p value 
Overall 59 28 (47,5) 31(52,5) 0.172 
Within 7 days 35 16 (45,7) 19(54,3) 0.856 
     
Birth weight < 2,5kg 62 13(21,0) 49(79,0) 0.698 
Birth weight < 1,5kg 
(VLBW) 
35 7(20,0) 28(80,0) 
  
Birth weight < 1kg 
(ELBW) 
13 3(23,1) 9(69,2) 
  
          
System involved       0.066 
Respiratory 76 25 (32,9) 51(67,1)   
GIT 36 13 (36,1) 23(63,9)   
Any malignancy 24 16 (66,7) 8(33,3)   
Diabetes 8 3 (37,5) 5(62,5)   
HIV exposed 24 8(33,3) 16(66,7)   
          
Steroids 44 21(47,7) 23(52,3) 0.314 
3rd  generation 
Cephalosporin  
56 26(46,4) 30(53,6) 
0.341 
Meropenem 54 14(25,9) 40(74,1) 0.005 
Aminoglycoside 84 27(32,1) 57(67,9) 0.015 
Vancomycin 44 12(27,3) 32(72,7)  0.027 
Chemotherapy 15 9(60,0) 6(40,0) 0.123 
2 or more antibiotics 112 41(36,6) 71(63,4) 0.078 
Cotrimoxazole 22 18(81,8) 4(18,2) <0.001 
Proton pump inhibitor 7 1(14,3) 6(85,7) 0.138 
Fluconazole 27 9(33,3) 18(66,7) 0.357 
Amphotericin B  15 5(33,3) 10(66,7)  0.510 
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 Total  
C. albicans 
Number (%) 
*Candida 
species other 
than C. 
albicans   
Number (%) p value 
Central Lines 118 46(39,0) 72(61,0) 0.342 
Ventilation 81 21(25,9) 60(74,1) <0.001 
Abdominal surgery 36 12(33,3) 24(66,7) 0.272 
*Candida species other than C. albicans    includes C. glabrata, C. parapsilosis, C. krusei, C. 
tropicalis and C. lusitaniae 
 
2.1.7 Medicines  
Steroid use was similar across all groups with 20/71 (28.16%), 13/55 (23.63%) and 9/41 
(21.9%) in neonates. children and adults respectively (p= 0.264). Antibiotic use differed 
across all groups with 112/167 (67.4%) of patients having received at least 2 broad spectrum 
drugs prior to the blood culture being taken. Neonates (61/71, 85.9 %), were significantly 
more likely than children 39/55 (70. 9 %) and adults 12/41 (29. 3%) to have received at least 
2 antibiotics (p< 0.001)  
Beta lactam use was common throughout all age groups with some patients receiving a single 
drug simultaneously depending on other concomitant bacterial cultures.  Vancomycin, 
meropenem and aminoglycoside use was highest amongst neonates with 25/71 (35.21%) 
10/71 (14.08%) and 49/71 (69.01%) respectively in comparison to the other 2 groups (p 
<0.001). Co -trimoxazole was used as prophylaxis for Pneumocystis jirovecii infection in 
18/55 (32.7%) in paediatric oncology compared to adult oncology (4/41, 97.5%) (p = 0.026) 
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3 Chapter 3 
3.1 Discussion 
Candidaemia has gained momentum in the past few years as an opportunistic infection 
predominantly in nosocomial but also in community acquired infections. CHBH has a much 
higher incidence of candidaemia than most developed countries (Blyth et al., 2009, Bassetti et 
al., 2011). The differences in candidaemia distribution within this hospital were highlighted in 
this study: Candida species other than C. albicans especially C. parapsilosis comprising the 
largest number of isolates was mostly cultured from neonates compared to C. albicans in 
adults in general wards (Bassetti et al., 2015) and paediatric patients. Risk factors associated 
with the Candida species other than C. albicans infection were extremes of age, use of 
invasive devices e.g. mechanical ventilation and use of broad spectrum antibiotics (Cotten et 
al., 2006). Prolonged hospital stays (> 7 days) noted in all age categories with neonates 
having the longest (15 days), have been associated with nosocomial infections (Blyth et al., 
2009; Menzin et al., 2009; Zaoutis et al., 2005). Additionally, the presence of multiple risk 
factors for a prolonged period could be drivers for antifungal resistance. In this study, 
fluconazole resistant C. parapsilosis was cultured mostly from neonates and significant risk 
factors included the neonate category, involvement of the respiratory system, mechanical 
ventilation, use of a prior antifungal and use of 2 or broader spectrum antibiotics. The  overall 
mortality rate was 35.3%  with the  was highest number of deaths amongst adults with C. 
albicans infection 15/22 (68.18) in keeping with other studies (Garnacho-Montero et al., 
2010; Gokcebay et al. 2016). Significant risk factors associated with in- hospital mortality 
was use of central lines, urinary catheters, total parenteral nutrition, 2 or more antibiotics, beta 
lactam - beta lactamase inhibitor, proton pump inhibitor, aminoglycoside and abdominal 
surgery  
3.1.1 Demographics 
Similarities in incidence rates to previous studies (Blyth et al., 2009) were noted in neonates 
having the highest and adults the lowest rates (Blyth et al., 2009). However, the main 
difference in incidence rates was the higher overall incidence at CHBH, 2.09 per 1000 
admissions, almost double compared to similar studies (Blyth et al., 2009, Bassetti et al., 
2011). The hospital experiences a high volume of admissions (estimated 150 000 in patients, 
500 000 outpatients and 350 accident and emergency and 60 000 maternity patients per year) 
(URL:  https://www.chrishanibaragwanathhospital.co.za/ (accessed 8.22.16). The high 
incidence may be due to a number of factors.  With over 20% HIV positivity rates in the 
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province and antenatal HIV prevalence almost 30% (Dramowski et al, 2011), a large 
proportion of patients are immunocompromised with paediatric in -patient mortality reaching 
46.1% (Dramowski et al, 2011).  Additionally, blood taking practices would usually be 
dictated by the patient and severity of clinical condition e.g. severely ill patients with 
suspected sepsis might have blood cultures drawn on admission to an ICU whereas a patient 
admitted for elective surgery would not.  The volume of blood taken is also important as this 
is problematic in certain patients especially paediatric and neonates because of the low blood 
volumes submitted for culture.  Adherence to infection control policies can be difficult in 
resource constrained settings due to limitations with staff numbers, high patient volumes, 
equipment availability e.g. single use items, care of in -situ devices like central lines and 
feeding practices including milk preparation. This would predispose patients to nosocomial 
infections and subsequent outbreaks. Concomitant bacterial infections would also drive 
antibiotic use and increase the selective pressure for resistant bacterial and fungal infections.  
Inappropriate antifungal prophylaxis, e.g. use of fluconazole when the dominant isolate in a 
unit is an azole resistant species, would also be a driver for continuing nosocomial 
transmission. Even though central line care and other infection control measures have not 
been measured, when coupled with other factors including underlying medical conditions, 
severe immunosuppression and prematurity, most likely contribute to the high rates observed.  
 
The largest number of patients in this study were children under 1 year of age with more than 
two thirds being neonates who were premature and of low birth weight (<2500 g). Due to the 
above factors, most required life- saving interventions like central lines, prolonged 
mechanical ventilation, steroids and either empiric or prophylactic broad spectrum antibiotics. 
Prematurity, ICU admission, use of central lines, prior use of broad spectrum antibiotics 
including the use of more than 2 drugs, GIT surgery and mechanical ventilation have all been 
shown to be risk factors for neonatal candidaemia (Blyth et al., 2009, Liu et al., 2015, Saiman 
et al., 2000, Lee et al., 2014, Festekjian A et al., 2012). We confirmed associations with 
mechanical ventilation and broad spectrum antibiotic use in this study. 
The neonatal unit had not only the highest number of cases overall, but also the largest 
number of admissions (1524 patients) for the study period. Neonates are rapidly colonised 
mainly in the gastrointestinal and respiratory tracts within 2 weeks after birth (Saiman et al., 
2000, Manzoni et al., 2007, Huang et al., 1998). Since fungal colonisation has been shown to 
be a risk factor for progression to candidaemia, this coupled with the other risk factors for 
neonates especially prematurity and birth weight, could explain the high burden seen in this 
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group. Subsequent nosocomial infection with a different species could explain the mixed 
cultures that were more common amongst this group compared to the adults and paediatrics.   
The prolonged length of stay before the first positive blood culture in neonates was 15 days, 
more than double that noted in other studies (Lee et al., 2013). More than a quarter of these 
babies also had medical and surgical interventions due to prematurity and low birth weights 
requiring prolonged stays in the unit, medical devices in situ and ventilation. Factors linked to 
infection control previously mentioned like overcrowding and difficulties in implementing 
local infection control policies combined with risk factors for the age group would all have 
predisposed to nosocomial infections (Vaz et al., 2011). These would need to be investigated 
and delineated to allow for appropriate application of local infection control protocols.  
Even though central line use was high in neonates, it was not statistically significant even 
though the majority of Candida species other than C. albicans cultured were C. parapsilosis. 
This species is known to be associated with line colonisation and line sepsis (Vaz et al., 
2011). However, in our study, it was not always clear as to the site of the blood culture, i.e. 
line or peripheral. It is plausible that cultures could reflect either colonisation of a line or the 
skin, or pseudofungemia from external contamination. This could happen when blood is first 
used for blood gas analysis before being inoculated into blood culture bottles.  Further 
detailed study of phlebotomy techniques would be required to determine this.   
Routine fluconazole prophylaxis for 42 days in preterm or very low birth weight babies had 
not been instituted at the time of the study. Use has been shown to decrease the incidence of 
invasive candidiasis but did not have any effect on mortality or increases in azole resistance 
(Ericson et al., 2014, Che et al., 2016, Cleminson et al., 2015). However, considering the 
fluconazole resistance rates of > 50% within C. parapsilosis isolates (overall fluconazole 
resistance in all species just under 20%) especially in neonates, the impact of fluconazole 
prophylaxis would be negligible in that unit. Additionally, the selection pressure from azole 
use could potentially drive the rates of resistance even higher within this species as well as 
within those which are inherently resistant e.g. C. lusitaniae. This would make choice of 
empiric antifungals difficult considering the limited antifungal classes available to the public 
sector.  
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3.1.2 Mortality 
Overall mortality was more than one third with the highest proportion of deaths recorded in 
the adults admitted to general medical wards (almost half). Although this rate is lower than 
the 60% previously stated by Kreusch et al in the same setting, it is in keeping with other 
studies limited to single tertiary centres (Bassetti et al., 2011).  The severity of the underlying 
condition could also have impacted on the choice and timing of treatment as well (Garey et 
al., 2006, Morrell et al., 2005).   
Most of the factors associated with mortality in this study have been previously described 
(Bassetti et al 2011, Horn et al 2008). All of these are usually interventions in high or 
intensive care requiring antibiotics as prophylactic or empiric for concomitant infections. 
Removal or change of devices, if not done timeously would also serve as foci for infection. 
The highest species specific crude mortality rates were in adults infected with C. albicans. 
Due to the other clinical risk factors associated with this group, not all cases of death could be 
directly ascribed to candidaemia. The high C. albicans rate noted is in keeping with other 
studies where C. parapsilosis and C. glabrata had the lowest mortality rates in adults 
(Bassetti et al., 2015, Horn et al., 2008). Possible reasons for this could be:  treatment of 
concomitant bacterial or viral infections with broad spectrum antibiotics and of fungaemia 
coupled with pre -existing risk factors like diabetes could have been a major contributor, 
continued presence of medical devices like central lines serve as a continuous infective focus 
in spite of treatment and inappropriate antifungal treatment.   
 
3.1.3 Species  
Candida epidemiology in this study is in keeping with other studies overall (Bassetti et al., 
2013, Blyth et al., 2009, Bassetti et al., 2015). Within each age cohort, there are some 
differences.  In neonates and paediatrics, C. parapsilosis and C. albicans were the 2 was most 
frequently isolated organisms similar other studies (Blyth et al., 2009.  Compared to the 
previous study conducted at CHBH in adults (Kreusch et al., 2013), C. albicans fell from 62% 
to 53%, while C. parapsilosis and C. glabrata dropped from 27 and 29% to 21% for both 
organisms in adults.   
The general distribution of Candida species other than C. albicans and C. albicans varied 
amongst the different patient groups and wards. C. albicans was still the most common isolate 
in the general medical wards (Bassetti et al., 2015).  In keeping with global trends this study 
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demonstrated the following: Candida species other than C. albicans were the commonest 
species isolated in children under 1 year of age and adults in ICU. This group (Candida 
species other than C. albicans) was also associated with risk factors for fungaemia – extremes 
of age, use of broad spectrum antibiotics and interventions like ventilation.  
 
3.1.4 Clinical diagnoses 
Significant associations have been noted between candidaemia, immunosuppression and 
infecting species (Kreusch et al 2013., Tumbarello et al., 1999, Taunay et al., 1998, 
Marukutira et al., 2014). HIV positive patients as well as diabetics would already have 
multiple risk factors for ICI. It is feasible due to the underlying medical conditions, possible 
multi organ involvement was already established on admission resulting in more septic 
patients.  C. albicans and C. parapsilosis have been noted to be 2 of the most frequently 
isolated yeasts in HIV positive patients (Marukutira et al., 2014).  
 
3.1.5 Laboratory 
Use of traditional biomarkers like the platelet count have been based on the immunology and 
interplay between fungi and platelets. However, changes in platelet counts can be difficult to 
attribute to a particular cause especially in high risk patients with multiple risk factors.  In this 
cohort, the median platelet counts for all groups were below the normal range stipulated by 
the laboratory with the neonates having the lowest values. For neonatal candidiasis, this is in 
keeping with other studies where low counts were helpful indicators (Zhao et al., 2014) for 
diagnosing ICI. Use of 1.3 β –D glucan as a biomarker to aid in diagnosis (Mackay et al., 
2011) and prognosticate ICI (Zhao et al., 2014) in different patient populations has been used. 
Even though this test has been noted to have lower sensitivity in C. parapsilosis infections 
(Mikulska et al., 2016), in this study the specimens from neonates, demonstrated high 1.3 β –
D glucan values. This could be indicative of a high burden of infection or a higher organism 
load if the sample is taken from an infected/colonised line. Further laboratory and clinical 
investigation would be required to establish this.  The converse could apply to oncology 
patients could have negative 1.3 β –D glucan (blood sampled from the uninfected port) but 
positive blood cultures taken peripherally.   
 
Isolate identification and susceptibility results guiding treatment were from the CHBH 
laboratory and polymicrobial blood cultures were identified at NICD. This could have been 
36 
 
due to a number of reasons at CHBH e.g. colony morphology of different species could have 
been difficult to differentiate and as antifungal susceptibility tests are read at 80% of 
inhibition, differences could easily have been missed due to subjective variation in reading. 
The other methods used at the reference laboratory like utilisation of chromogenic media, 
would have enhanced phenotypic differences enabling easier differentiation of isolates and 
subsequent isolate specific antifungal susceptibility testing. This could have impacted 
negatively on choice of antifungal for treatment especially for mixed cultures as the 
predominant isolate, possibly the azole susceptible one, would have dictated empiric 
treatment.  
 
3.1.6  Azole susceptibility 
The high rates of azole resistant C. parapsilosis is cause of concern in this hospital. This was 
significant, considering that 14.3% of  patients on an azole empirically or prophylactically 
were diagnosed with ICI. High azole resistance impacts choice of empiric and prophylactic 
antifungal agents in an already resource constrained setting (Govender et al., 2016). 
Furthermore, nosocomial infection, continuous presence of risk factors and prolonged use of 
antifungals would also increase the selective pressure and contribute to spread. Molecular 
techniques could be used to elucidate if strain specific outbreaks are occurring and 
subsequently aid in choice of empiric treatment (Dizbay et al, 2008).  
 
3.1.7 Strengths and limitations 
The retrospective nature of this study meant that not all of the patient files could be located 
and thus had to be excluded. Even though this represented a degree of bias, overall, the 
numbers for each group analysed were proportional to the excluded files. The age and prior 
antifungal category showed significant differences between both groups (age p <0.001; prior 
antifungal given p = 0.001). For neonates, a significantly higher percentage (>50%) of records 
could not be located compared to a lower % for other age groups  
Data regarding concomitant bacterial and other viral infections was not collected and thus 
correlation with multiple antibiotic use was not done. Patients were not followed up long term 
to determine morbidity. Information was not always available regarding central line or urinary 
catheter duration or removal. Patient records did not always indicate if antifungal treatment 
was prophylactic or empiric or if combination therapy was utilised once ICI was confirmed. 
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Since hospital data for oncology was not readily available, the incidence in adult oncology 
could not be calculated.  
Blood culture sensitivity for fungal infections is low (Nguyen et al., 2012) and likely worse in 
neonates and paediatrics due to the limitations on volume, hence multiple cultures taken prior 
to this might have been negative leading to delays in empirical treatment.  On the other hand, 
improved clinical suspicion, earlier initiation of empiric antifungal therapy and improved use 
of biomarkers in addition to traditional blood cultures would have contributed to non - culture 
based diagnoses.  
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3.2 Conclusion 
Overall this study highlights the association of multiple risk factors e.g. invasive devices and 
use of broad spectrum antibiotics in a hospital setting that contribute to candidaemia.  
The differences within units influences antifungal choice for both empiric and prophylactic 
treatment. Predominance of non-C. albicans species combined with the high burden of 
fluconazole resistant isolates noted in neonates and mixed cultures, use of a broad-spectrum 
antifungal such as amphotericin B would be indicated until definitive identification and 
susceptibility testing can be done.  Multi- disciplinary educational initiatives targeting 
infection control and a unit specific antifungal stewardship programme nosocomial infections.   
The antifungals that could be used empirically for each group based on this study would 
include fluconazole for both paediatrics and adults and amphotericin B for neonates. 
Considering the side effect profile of amphotericin B, use of alternate classes like the 
echinocandins would need to be explored further in neonates. Considering that complicated 
Candida infection occurs quite commonly in neonates, i.e. meningitis, echinocandin use 
would also be limited as this drug does not penetrate the cerebrospinal fluid. Thus, the 
pharmacokinetic and pharmacodynamics properties of the antifungal would need to be taken 
into account to allow for adequate concentrations at the site of infection. 
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